"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial of apixaban to prevent blood clots in people with myeloma (TiMM)
This trial compared apixaban with other blood thinning medications to see if it works as well and whether it has fewer side effects.
It was open for people to join between 2016 and 2017, and the team published the results in 2019.
More about this trial
Doctors assess people’s risk of developing a blood clot and decide which treatment is best. When this trial was done:
- people with a standard risk had a low dose of aspirin
- people with a high risk had low molecular heparin (such as enoxaparin)
Both these medications prevent blood clots by thinning the blood. Apixaban (Eliquis) is another medication that thins the blood.
Doctors had already used apixaban to prevent blood clots in people with other medical conditions. They hoped that it would be as good as aspirin or enoxaparin for people with myeloma. And that it might have fewer side effects.
The trial team wanted to know if it is possible to do a large clinical trial comparing apixaban with aspirin and enoxaparin. They needed to do a small feasibility trial first.
The main aims of this feasibility trial were to find out:
- whether it is safe for people with myeloma to take apixaban
- what people think about taking part in this sort of trial
- how well apixaban prevents blood clots
Summary of results
The trial team found that it was safe for people with myeloma to take apixaban, and that it should be possible to run a larger trial.
- those who had a high risk of developing a blood clot had either apixaban or enoxaparin
- those who had a standard risk of developing a blood clot had either apixaban or aspirin
You have enoxaparin as an injection under the skin once a day. Aspirin is a tablet you have once a day with food. Apixaban is a tablet you have twice a day.
The people taking part had the first blood thinning treatment on the day they started chemotherapy, and then every day for up to 6 months after that. They saw the doctor every 3 weeks, on the same day they had chemotherapy.
A total of 10 people joined the trial, 2 who had high risk and 8 who had standard risk of developing a blood clot.
The 2 people at high risk were put into 1 of 2 treatment groups at random:
- 2 people had apixaban
- 0 people had enoxaparin
The 8 people with standard risk were also put into 1 of 2 treatment groups at random:
- 4 people had apixaban
- 4 people had aspirin
The research team held a focus group meeting and asked 5 patients and 2 carers about things such as:
- what they knew about the risk of developing blood clots with myeloma
- what they thought about taking part in clinical trials in general
- what they thought about taking part in this trial in particular
- how they felt about taking part in more than one trial at the same time
The results showed that people didn’t know much about the increased risk of developing a blood clot with myeloma. The team found that people weren’t told much or given written information about it. Or if they had been told, they had been given so much other information they had forgotten.
People generally felt that it was good to take part in clinical trials. But some people felt it was more important to focus on treating the myeloma itself.
There was an issue with some other trials stating that people couldn’t join another trial at the same time. Patients are often happy to take part in more than one trial if they are allowed to. The research team felt that it would be useful for some trials to be more flexible about people also being part of another trial.
Three people who took part had mild bleeding problems – two who were having aspirin and one who was having apixaban. No one had any serious bleeding problems.
Two people had a small blood clot where they had a small needle (cannula) in their arm to have chemotherapy. No one had a larger or more serious clot such as a deep vein thrombosis (DVT).
The team found that it should be possible to run a larger trial looking at apixaban in more detail.
They asked 11 people if they’d like to join the TiMM trial and 10 people (91%) said they would. But they may need to look at who can join the trial (the eligibility criteria) and make a few changes, so it is easier for more people to take part.
The trial team concluded that they didn’t have any concerns about how safe apixaban is, or how well it works. And that, with a few changes, they should be able to run a larger trial to find out more about well it works.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Roopen Arya
King’s College Hospital NHS Foundation Trust,
National Institute for Health Research (NIHR)
NIHR Clinical Research Network: Cancer